Safety and efficacy of DTaP-IPV vaccine use in healthcare workers for prevention of pertussis. Issue 40 (25th September 2018)

• Record Type: Journal Article
• Authors: Shimizu, Hiroyuki; Seki, Kazuo; Shiga, Kentaro; Nakayama, Tetsuo; Mori, Masaaki
• Is Part Of: Vaccine. Volume 36:Issue 40(2018)
• Page Start: 5935
• Page End: 5939
• Publication Date: 2018-09-25
• Subjects: Bordetella pertussis -- Diphtheria-tetanus-acellular pertussis and polio (DTaP-IPV) -- Pertussis toxin (PT) -- Filamentous hemagglutinin (FHA) -- Fimbriae 2 (Fim2) -- Fimbriae 3 (Fim3); Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.08.047
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Vaccination with the reduced antigen DTaP-IPV (0.2 mL) successfully provides effective immunity. Seropositivity is maintained ten months after vaccination even with 0.2 mL DTaP-IPV. The 0.2 mL DTaP-IPV vaccine is safe and well-tolerated. Vaccination with 0.2 mL DTaP-IPV is safe and effective alternative to Tdap. Abstract: Pertussis can be fatal for infants. The best way to prevent infant pertussis is to promote adult immunization. However, Tdap has not been licensed in Japan, so we investigated the effect and safety of the DTaP-IPV vaccine instead. The study examined 154 pediatric healthcare workers. Participants without effective levels of antibodies against pertussis toxin were given DTaP-IPV, reduced to 0.2 mL. In total, 48 of the 154 participants (31.2%) were seronegative for pertussis toxin. After vaccination of the seronegative participants, 40 of the 41 measured (97.5%) had acquired an effective response, and all 35 of those tested maintained a protective antibody level ten months after vaccination. Redness was observed in 14 of the 41 (34.1%) and soreness in 19 (46.3%). This study demonstrated that vaccination with reduced 0.2 mL DTaP-IPV successfully provided effective immunity. At least ten months after vaccination, all subjects maintained an adequate level of antibodies.